Neurological Biomarkers Market Report 2025 (Global Edition)

Global Neurological Biomarkers Market Report 2025 Market Size Split by Imaging techniques (Transcranial magnetic stimulation (TMS), Diffusion tensor imaging (DTI), Conventional structural MRI (sMRI), ...

Neurological Biomarkers Market Report Description

We have various report editions of Neurological Biomarkers Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Neurological Biomarkers Market Insights Video

Competitive Landscape of the Neurological Biomarkers Market

The major firms rapidly adapt new strategies to gain a competitive advantage and market share. The primary Neurological Biomarkers market participants prioritise expanding creative products to serve a big consumer base and acquire a competitive advantage.

• March 2023, Abbott Laboratories announced the FDA approval of the Alinity i laboratory traumatic brain injury (TBI) blood test, the first of its type, which will aid medical professionals in evaluating people who have suffered mild TBIs.

Top Companies Market Share in Neurological Biomarkers Industry: (In no particular order of Rank)

• Abbott
• Thermo Fisher Scientific Inc.
• Merck & Co. Inc.
• Bio-Rad Laboratories Inc.
• Johnson & Johnson Services Inc.
• DiaGenic ASA
• BANYAN BIOMARKERS INC.
• Quanterix
• Alseres Pharmaceuticals Inc.
• Rules-Based Medicine
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

North America dominated the market in 2023 and accounted for around 43% of the global revenue

According to Cognitive Market Research, North America dominated the market in 2023 and accounted for around 43% of the global revenue; the region's expansion can also be linked to a growing appreciation of biomarkers' enormous potential in medication development. The presence of regulatory agencies in the region will also likely boost the development of biomarker-based drugs shortly. This is primarily because these organizations are critical in raising public awareness about the promise of biomarker-based medicines in illness management.

Europe is the fastest-growing category as the necessity for early detection of neurological illnesses, which would aid in lowering treatment costs and mortality, is likely to drive market expansion in the region. The local presence of major biomarker companies aided in expanding R&D investments, driving the creation of novel biomarkers to meet the region's expanding demand for early diagnosis.

The current report Scope analyzes Neurological Biomarkers Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Neurological Biomarkers Market

According to Cognitive Market Research, North America held the major market of more than 43% of the global revenue, with a market size of USD 3.23 billion in 2023. It will grow at % compound annual growth rate (CAGR) of 11.0% from 2023 to 2030. North America is a growing neurological biomarker industry hub, distinguished by cutting-edge research, cutting-edge technologies, and a strong healthcare infrastructure. The region's emphasis on precision medicine and neurology research drives biomarker adoption for early diagnosis and individualized treatment techniques. Research institutions, hospitals, and biopharmaceutical firms work closely together in this fast-paced sector to enhance biomarker discovery and validation. The increasing frequency of neurological illnesses and the desire for innovative diagnostic solutions contribute to the market's growth in North America. The region remains a key player in shaping the worldwide landscape of neurological biomarkers, focusing on increasing neurology diagnoses and therapy.

Europe Neurological Biomarkers Market

According to Cognitive Market Research, with a market value of USD 2.10 billion in 2023 and projected to expand at a compound annual growth rate (CAGR) of 11.3% from 2023 to 2030, Europe accounted for the majority of global revenue, accounting for over 28% of the total with a sophisticated healthcare infrastructure and a dedication to neurology research advancement. The region's diversified demographic composition adds to a wide range of neurological illnesses, increasing demand for precise diagnostic tools and individualized treatment approaches. Biomarker development and validation require considerable collaboration among research institutions, hospitals, and biopharmaceutical businesses, fueling market growth. The region's leadership in cutting-edge research and concentration on new healthcare solutions position Europe as a key influencer in shaping the worldwide landscape of neurological biomarkers, with a focus on improving patient outcomes and driving breakthroughs in neurology diagnostics.

Asia Pacific Neurological Biomarkers Market

According to Cognitive Market Research, Asia Pacific held a considerable market share in 2023, accounting for more than 22% of the global revenue with a market size of USD 0.38 billion in 2023 and will grow at a compound annual growth rate (CAGR) of 13.0% from 2023 to 2030 With a growing emphasis on healthcare improvements and increased neurological research efforts, Asia Pacific is developing as a dynamic participant in the neurological biomarkers market. The region's diversified population has a high frequency of neurological disorders, fueling the demand for precise diagnostic solutions. Biomarker research and development is fueled by collaboration between research institutes and healthcare facilities. As people become more aware of personalized medicine, Asia Pacific is seeing increased biomarker use for neurology diagnosis. The Asia Pacific, neurological biomarkers market, is poised for significant growth as the region becomes a focus point for clinical trials and research activities, adding to the worldwide landscape of neurology diagnostics and personalized medicine.

South America Neurological Biomarkers Market

According to Cognitive Market Research, Latin America accounted for more than 2% of the global Neurological Biomarkers revenue in 2023, with a market size of USD 0.15 billion in 2023. It will grow at a compound annual growth rate (CAGR) of 13.1% from 2023 to 2030, owing to a dynamic healthcare landscape and a growing emphasis on neurological research. The region's specific demographic factors lead to a high prevalence of neurological illnesses, necessitating the development of precise diagnostic methods. While research and development projects in conjunction with worldwide entities are underway, there is a rising emphasis on improving neurology diagnoses. The Latin American neurological biomarkers market offers potential prospects, coinciding with worldwide trends in personalized medicine and precision diagnostics. As the area invests in healthcare infrastructure and research skills, it is poised to contribute to the global neurological biomarkers market.

Middle East and Africa Neurological Biomarkers Market

According to Cognitive Market Research, the Middle East and Africa accounted for more than 4% of the global revenue in 2023, with a market size of USD 0.3billion in 2023. They will grow at a compound annual growth rate (CAGR) of XX% from 2023 to 2030. The region's unique healthcare issues, as well as the frequency of various neurological disorders, add to the need for sophisticated diagnostic technologies. Biomarker discovery and development are being driven by research collaborations, particularly in major healthcare centres. While the market is changing, there is a clear focus on enhancing neurology diagnostics. The Middle East and Africa's contribution to the market for neurological biomarkers is consistent with worldwide developments in personalized medicine. As the area invests in healthcare infrastructure and research skills, it is positioned to play a critical role in influencing the worldwide neurological biomarkers market.

Neurological Biomarkers Market Analysis

Neurological Biomarkers Imaging techniques Segment Analysis

According to Cognitive Market Research, transcranial magnetic stimulation (TMS) held the major market share over the forecast period. TMS, a non invasive neurostimulation technology, contributes to understanding and identifying neurological biomarkers linked to various illnesses. Its use in research and diagnostics aids in developing new biomarkers, which improves our understanding of neurological disorders and promotes advancements in customized medicine in the neurological domain. This, in turn, favours the market for neurological biomarkers' growth and evolution.

Functional magnetic resonance imaging (fMRI) is the fastest-growing category over the forecast period. This noninvasive imaging approach allows for detecting and comprehending functional biomarkers linked to neurological diseases. The ability of fMRI to record brain activity and detect anomalies advances neurology research and diagnostics. Its use benefits the neurological biomarkers market by giving significant insights into the brain's complex workings in various clinical settings.

• Transcranial magnetic stimulation (TMS)
• Diffusion tensor imaging (DTI)
• Conventional structural MRI (sMRI)
• Functional magnetic resonance imaging (fMRI)
• Positron emission tomography (PET)

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Neurological Biomarkers Industry. Request a Free Sample PDF!

Neurological Biomarkers Application Segment Analysis

According to Cognitive Market Research, Proteomics biomarkers hold a prominent market share. Proteomics, which uses modern technology, allows for identifying protein biomarkers related to neurological illnesses. This method improves diagnostic precision and specificity while contributing to a better knowledge of neurological diseases. As proteomics advances, its use in biomarker identification accelerates breakthroughs in customized treatment in the neurological domain, favourably boosting market growth.

Imaging-based biomarkers are the fastest-growing category over the forecast period. Noninvasive imaging techniques like MRI and PET scans allow for observing and identifying structural and functional abnormalities in the brain associated with neurological diseases. These imaging biomarkers are critical in illness detection, monitoring, and treatment evaluation. The increased dependence on imaging-based biomarkers improves the precision and efficacy of neurological diagnostics, propelling the industry forward.

• Proteomics based biomarkers
• Genomic based biomarkers
• Imaging based biomarkers
• Metabolic based biomarkers

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Neurological Biomarkers Indication Segment Analysis

According to Cognitive Market Research, Alzheimer's disease (AD) holds a prominent market share. Researchers and doctors increasingly rely on biomarkers in Alzheimer's patients for early identification, monitoring disease progression, and assessing therapy efficacy. This focus on generating precise and sensitive biomarkers for Alzheimer's disease improves diagnostic precision and treatment interventions, contributing to the growth and advancement of the neurological biomarkers market. 

Parkinson's disease (PD) is the fastest-growing category over the forecast period; the search for distinct and accurate biomarkers for Parkinson's disease early diagnosis and surveillance has intensified. Biomarkers contribute to the study of illness mechanisms and the evaluation of therapy effects. Identifying different neurological biomarkers linked with Parkinson's disease adds to advances in precision medicine, supporting favourable growth dynamics in the neurological biomarkers market as research advances. 

• Alzheimer's disease (AD)
• Multiple sclerosis (MS)
• Parkinson's disease (PD)
• Autism spectrum disorder (ASD)

Neurological Biomarkers End-user Segment Analysis

According to Cognitive Market Research, research laboratories hold a prominent market share. These facilities are at the heart of biomarker development, validation, and research projects on neurological illnesses. Research laboratories contribute to the identification of novel biomarkers, improving diagnostic precision and treatment interventions through cutting-edge technologies and collaborative efforts. The dynamic work done in these facilities favours the neurological biomarkers market, supporting advances in neurology research and customized treatment.

Hospitals are the fastest-growing category over the forecast period. As diagnostic and treatment facilities, hospitals use biomarkers for neurological illnesses to improve patient care. The use of biomarkers in everyday clinical practice assists in the early detection and monitoring of neurological disorders. This application in hospital settings greatly contributes to the growth of the neurological biomarkers market, improving patient outcomes and boosting neurology research.

• Hospitals
• Clinics
• Diagnostic and research laboratories

Author's Detail

Sneha Mali

Research Analyst at Cognitive Market Research

LinkedIn

Profile

I am a research analyst working in various domains including the Consumer Goods domain, and my primary responsibility is to conduct thorough research on various subjects and provide valuable insights to support client requirements. I have knowledge of research methodologies, and data mining which enables me to analyze large data sets, draw meaningful conclusions, and communicate them effectively. I stay up-to-date with the latest research trends, methodologies, and technologies to ensure that my research is accurate, relevant, and impactful.

Author's Conclusion